Abstract
To establish whether multiple sclerosis (MS) patients, who have lost the therapeutic effect of interferon-beta (IFN-beta) owing to neutralizing antibodies (NAbs) and subsequently revert from a NAb-positive to a NAb-negative state under continued IFN-beta-1b therapy, regain clinical effect after reversion.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Multiple Sclerosis |
Vol/bind | 14 |
Udgave nummer | 6 |
Sider (fra-til) | 837-42 |
Antal sider | 6 |
ISSN | 1352-4585 |
DOI | |
Status | Udgivet - 1 jul. 2008 |
Udgivet eksternt | Ja |